AP NEWS

X4 Pharmaceuticals to Present Clinical Data from Phase 2 Expansion Study of Combination of X4P-001-IO and Inlyta® (axitinib) in Patients with Clear Cell Renal Cell Carcinoma

May 16, 2018

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 16, 2018--X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that an abstract highlighting X4P-001-IO, the company’s CXCR4 antagonist, has been selected for poster presentation at the 2018 Association Society of Clinical Oncology (ASCO) annual meeting, taking place June 1-5 in Chicago. The presentation will describe clinical results from the Phase 2 expansion of an ongoing Phase 1/2 study of X4P-001-IO in combination with Inlyta® (axitinib) in patients with clear cell renal cell carcinoma (ccRCC).

Details of the presentation on X4P-001 are as follows:

About X4P-001-IO in Cancer

X4P-001-IO is an investigational selective, oral, small molecule antagonist of C-X-C receptor type 4 (CXCR4). CXCR4 is a chemokine receptor present in abundance on certain immune cells and cancer cells and it plays a critical role in immune cell trafficking, infiltration and activation in the tumor microenvironment. CXCR4 signaling is disrupted in a broad range of cancers, facilitating tumor growth by allowing cancer cells to evade immune detection and creating a pro-tumor microenvironment. X4P-001-IO has the ability to help restore immunity within the tumor microenvironment and has the potential to enhance the anti-tumor activity of approved and emerging oncology agents, such as checkpoint inhibitors and targeted therapies. X4P-001-IO is being investigated in several clinical studies in solid tumors.

About X4 Pharmaceuticals

X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat cancer and rare diseases. The Company’s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4’s most advanced product candidate, X4P-001-RD, is in a Phase 2/3 study in patients with WHIM syndrome, a rare genetic, primary immunodeficiency disease. X4P-001-IO is currently under investigation in multiple clinical studies in solid tumors. X4 was founded and is led by a team with deep product development and commercialization expertise, including several former members of the Genzyme leadership team, and is located in Cambridge, MA. For more information, visit  www.x4pharma.com.

Inlyta® is a registered trademark of Pfizer.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180516006462/en/

CONTACT: X4 Pharmaceuticals

Kathryn Morris, 914-204-6412

kathryn@theyatesnetwork.com

KEYWORD: UNITED STATES NORTH AMERICA ILLINOIS MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL

SOURCE: X4 Pharmaceuticals

Copyright Business Wire 2018.

PUB: 05/16/2018 05:00 PM/DISC: 05/16/2018 05:00 PM

http://www.businesswire.com/news/home/20180516006462/en

AP RADIO
Update hourly